OpenOnco
UA EN
Plan Builder Onco Wiki Tumor Board

Onco Wiki / Red flag

PMF with anemia as dominant clinical problem (Hb <10 g/dL OR transfusion-dependent) — mom...

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

IDRF-PMF-ANEMIA-DOMINANT
TypeRed flag
Statusreviewed 2026-04-25 | pending_clinical_signoff
DiseasesDIS-PMF
SourcesSRC-COMFORT-I-VERSTOVSEK-2012 SRC-NCCN-MPN-2025

Red Flag Origin

DefinitionPMF with anemia as dominant clinical problem (Hb <10 g/dL OR transfusion-dependent) — momelotinib preferred over ruxolitinib (MOMENTUM trial: spleen + symptom + Hb improvement)
Clinical directioninvestigate
Categoryorgan-dysfunction

Trigger Logic

{
  "any_of": [
    {
      "comparator": "<",
      "finding": "hemoglobin_g_dl",
      "threshold": 10
    },
    {
      "finding": "rbc_transfusion_dependent",
      "value": true
    },
    {
      "finding": "anemia_dominant_pmf",
      "value": true
    }
  ],
  "type": "composite"
}

Notes

Direction "investigate" — surfaces JAKi-selection annotation. Momelotinib's ACVR1 inhibition lowers hepcidin → improves anemia vs ruxolitinib (which often worsens anemia). NOT registered in Ukraine — major access barrier. Alternative: ruxolitinib + ESA, or pacritinib (severe thrombocytopenia subtype). STUB — requires clinical co-lead signoff.

Used By

Algorithms

Indications